The Potential of hsa-mir-106b-5p as Liquid Biomarker in Prostate Cancer Patients in Indonesia

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 22; no. 3; pp. 837 - 842
• Main Authors: Bonnu, Christin H, Ramadhani, Anggia N, Saputro, Ranu B, Sesotyosari, Salsabila L, Danarto, R, Astuti, Indwiani, Haryana, Sofia M
• Format: Journal Article
• Language: English
• Published: Thailand West Asia Organization for Cancer Prevention 01.03.2021
• Subjects: Prostate Cancer; hsa-mir-106b-5p; nanoString; qRT-PCR
• ISSN: 1513-7368; 2476-762X
• DOI: 10.31557/APJCP.2021.22.3.837

This study aims to explore the potential of hsa-mir-106b-5p as a new liquid biomarker for prostate cancer sufferers in Indonesia. Analysis of hsa-mir-106b-5p expression of two tissue samples from BPH patients and two PCa patients used NanoString nCounter Expression Assay then validated by qRT-PCR using 10 patient urine samples for prostate cancer and BPH. Furthermore, analysis of the role of hsa-mir-106b-5p in prostate cancer was carried out bioinformatically. The results of this study indicated that the expression of hsa-mir-106b-5p in prostate cancer tissue was 1.23 times higher than that of BPH and urine of Indonesian patients (1.72 times). Moreover, this miRNA was upregulated in prostate cancer cells compared to normal cells 1.37 times. The hsa-mir-106b-5p appeared to be involved in the development of prostate cancer through the binding of genes involved in endoplasmic reticulum stress pathways and tumor suppressor genes. hsa-mir-106b-5p could modulate prostate cancer by interfering with the endoplasmic reticulum stress repair pathways and decreasing the expression of tumor suppressor genes involved in many biological processes. These updates our understanding of the role of hsa-mir-106b-5p in cancer and its potential as a candidate of a biomarker for clinical diagnosis of prostate cancer.